Interpace Diagnostics Announces Coverage of Thyroid Test by Oxford Health Plans
August 16, 2017 08:30 ET
|
Interpace Diagnostics Group
PARSIPPANY, N.J., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically...
Interpace Diagnostics Group Reports Second Quarter 2017 Financial Results, Business Progress and Recent Accomplishments
August 10, 2017 09:50 ET
|
Interpace Diagnostics Group
Net Revenue Grew 7% Over the Prior Year Comparable Quarter and 11% Over the First Quarter of 2017 Raised Over $22 Million in Capital in Past 6 MonthsEliminated All Long Term Debt and Related Royalties...
Interpace Diagnostics to Host Conference Call and Webcast to Discuss Second Quarter 2017 Financial Results on Thursday August 10, 2017
August 09, 2017 16:05 ET
|
Interpace Diagnostics Group
PARSIPPANY, N.J., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically...
Interpace Diagnostics Launches Product Extension at World Conference on Thyroid Cancer
August 01, 2017 08:00 ET
|
Interpace Diagnostics Group
BOSTON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or the “Company”), a fully integrated commercial company that provides clinically useful...
Interpace Diagnostics Announces Cigna Coverage of ThyGenX®
July 27, 2017 08:00 ET
|
Interpace Diagnostics Group
PARSIPPANY, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically...
Interpace Diagnostics Joins the Fight Against Pancreatic Cancer at the Pittsburgh PurpleStride Event
July 13, 2017 14:19 ET
|
Interpace Diagnostics Group
PARSIPPANY, N.J., July 13, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics (Nasdaq:IDXG) has joined the Pancreatic Cancer Action Network (PanCAN) to raise critical funds and awareness for pancreatic...
Interpace Diagnostics Announces National Contract with Aetna
June 28, 2017 08:15 ET
|
Interpace Diagnostics Group
PARSIPPANY, N.J., June 28, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically...
Interpace Diagnostics Announces Coverage of Thyroid Test By Premera Blue Cross
June 26, 2017 08:15 ET
|
Interpace Diagnostics Group
PARSIPPANY, N.J., June 26, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically...
Interpace Diagnostics Announces Closing of $13.7 Million Public Offering
June 21, 2017 11:40 ET
|
Interpace Diagnostics Group
PARSIPPANY, N.J., June 21, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (Nasdaq:IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically...
Interpace Diagnostics Announces Pricing of $13.7 Million Underwritten Public Offering of Common Stock and Common Warrants
June 16, 2017 09:00 ET
|
Interpace Diagnostics Group
PARSIPPANY, N.J., June 16, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (Nasdaq:IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically...